These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 18349433)

  • 21. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
    Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
    Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.
    Nichols BE; Götz HM; van Gorp EC; Verbon A; Rokx C; Boucher CA; van de Vijver DA
    PLoS One; 2015; 10(11):e0142576. PubMed ID: 26554586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.
    Nichols BE; Sigaloff KC; Kityo C; Hamers RL; Baltussen R; Bertagnolio S; Jordan MR; Hallett TB; Boucher CA; de Wit TF; van de Vijver DA
    J Int AIDS Soc; 2014; 17(1):19164. PubMed ID: 25491351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of early highly active antiretroviral therapy on viral suppression among newly diagnosed men who have sex with men living with human immunodeficiency virus in Xi'an, China.
    Wei X; Zhang Y; Santella AJ; Wang L; Zhuang G; Li S; Zhang H
    J Med Virol; 2019 Jul; 91(7):1263-1271. PubMed ID: 30840771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.
    Auvert B; Males S; Puren A; Taljaard D; Caraël M; Williams B
    J Acquir Immune Defic Syndr; 2004 May; 36(1):613-21. PubMed ID: 15097305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom.
    Long EF; Mandalia R; Mandalia S; Alistar SS; Beck EJ; Brandeau ML
    PLoS One; 2014; 9(4):e95735. PubMed ID: 24763373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting first month adherence due to antiretroviral therapy among HIV-positive adults at Felege Hiwot Teaching and Specialized Hospital, north-western Ethiopia; a prospective study.
    Tegegne AS; Ndlovu P; Zewotir T
    BMC Infect Dis; 2018 Feb; 18(1):83. PubMed ID: 29458343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.
    de Bruin M; Oberjé EJM; Viechtbauer W; Nobel HE; Hiligsmann M; van Nieuwkoop C; Veenstra J; Pijnappel FJ; Kroon FP; van Zonneveld L; Groeneveld PHP; van Broekhuizen M; Evers SMAA; Prins JM
    Lancet Infect Dis; 2017 Jun; 17(6):595-604. PubMed ID: 28262598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
    Johnson WD; Diaz RM; Flanders WD; Goodman M; Hill AN; Holtgrave D; Malow R; McClellan WM
    Cochrane Database Syst Rev; 2008 Jul; (3):CD001230. PubMed ID: 18646068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.
    Goldie SJ; Paltiel AD; Weinstein MC; Losina E; Seage GR; Kimmel AD; Walensky RP; Sax PE; Freedberg KA
    Am J Med; 2003 Dec; 115(8):632-41. PubMed ID: 14656616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.
    Neilan AM; Bulteel AJB; Hosek SG; Foote JHA; Freedberg KA; Landovitz RJ; Walensky RP; Resch SC; Kazemian P; Paltiel AD; Weinstein MC; Wilson CM; Ciaranello AL
    Clin Infect Dis; 2021 Oct; 73(7):e1927-e1935. PubMed ID: 32730625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa.
    Waters RC; Ostermann J; Reeves TD; Masnick MF; Thielman NM; Bartlett JA; Crump JA
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):443-52. PubMed ID: 21297484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.
    Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD
    J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.